vial of 0.1 mL concentrate (484R-14) vial of 0.1 mL concentrate Research Use Only (484R-14-RUO) vial of 0.5 mL concentrate (484R-15) vial of 1.0 mL concentrate (484R-16) vial of 1.0 mL concentrate Research Use Only (484R-16-RUO) vial of 1.0 mL pre-dilute Research Use Only (484R-17-RUO) vial of 1.0 mL pre-dilute ready-to-use (484R-17) vial of 25.0 mL pre-dilute ready-to-use Research Use Only (484R-10-RUO) vial of 25.0 mL pre-dilute ready-to-use (484R-10) vial of 7.0 mL pre-dilute ready-to-use (484R-18) vial of 7.0 mL pre-dilute ready-to-use Research Use Only (484R-18-RUO)
PRAME (PReferentially-expressed Antigen in MElanoma) is a gene encoded on the 22q11-22 chromosomal sequence and encodes a 509 amino acid residue protein.1 PRAME is a melanoma antigen that is preferentially expressed in tumors and is recognized by cytotoxic T lymphocytes.2,3 PRAME can be used to distinguish between malignant melanoma cells and nevus cells,4 and therefore may be useful for diagnostic purposes to support a suspected case of melanoma. PRAME is considered a cancer-testis antigen (CTA)5 and is not strongly expressed in most other normal tissues. PRAME is positively expressed in about half of uveal melanomas,6 and the majority of mucosal melanomas.7
品質
United States - IVD
Canada - RUO
European Union - IVD
Japan - RUO
外觀
Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and < 0.1% Sodium Azide.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 32(12), 1727-1733 (2019-08-04)
Mucosal melanomas are rare, and less is known about the biomarkers of this subtype in comparison to cutaneous or uveal melanomas. Preferentially expressed antigen in melanoma (PRAME) has been studied as a tool for prognostication of uveal melanomas, and immunotherapy
Uveal melanoma (UM) is an intraocular primary malignant neoplasm that often gives rise to metastatic disease for which there are no effective therapies. A substantial proportion of UMs express the cancer-testis antigen PRAME (preferentially expressed antigen in melanoma), which can
PRAME/MAPE/OIP4 is a germinal tissue-specific gene that is also expressed at high levels in haematological malignancies and solid tumours. The physiological functions of PRAME in normal and tumour cells are unknown, although a role in the regulation of retinoic acid
Melanoma lines MEL.A and MEL.B were derived from metastases removed from patient LB33 in 1988 and 1993, respectively. The MEL.A cells express several antigens recognized by autologous cytolytic T lymphocytes (CTL) on HLA class I molecules. The MEL.B cells have
The American journal of surgical pathology, 42(11), 1456-1465 (2018-07-26)
PRAME (PReferentially expressed Antigen in MElanoma) is a melanoma-associated antigen that was isolated by autologous T cells in a melanoma patient. While frequent PRAME mRNA expression is well documented in cutaneous and ocular melanomas, little is known about PRAME protein
